While cancer therapies are getting more personalized (and expensive), patient outcomes don’t seem to improve along the same trajectory and SynDevRx believes to know why that is. According to the company’s research the answer lies in the way that obesity, diabetes, and other forms of metabolic dysfunction accelerate tumor growth and metastasis, making at least 13 common types of cancer much more…
